Home Resources Living With Uterine Fibroids and Endometriosis US 2022

Living With Uterine Fibroids and Endometriosis US 2022

2 September 2022
Scroll

Living With Uterine Fibroids (UF) and Endometriosis (Endo) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs. These reports provide pharmaceutical companies with a strong, foundational knowledge and up-to-date insights on the UF and Endo patient journeys.

UF and Endo place a similar burden on women, their family and employment opportunities. Women’s health is starting to be discussed more widely, so necessary conversations are beginning to open up meaning more women are likely to seek HCP advice and treatment. The Living With UF and Endo reports have been conducted to help pharma identify how patients truly feel, perception of their current treatment options and unmet needs.

Both reports cover the US market, Living With UF (sample of 110 patients) and Living With Endo (sample of 111 patients). The methodologies consisted of 40-minute quantitative online interviews and a small sample of 40-minute qualitative telephone interviews, including patient diary tasks 1 week before the interviews.

Research Partnership has also recently launched new US reports in Living With CKD, PsA, Ankylosing Spondylitis. To find out more about these new reports or to request an information pack please contact us now.

Head of Living With, Mariel Metcalfe commented, “Research Partnership is committed to producing research which focuses on the voice of the patient, and to offer a more patient-centric view of what it is like to live with a long-term, life-changing illness. Our reports cover a wide range of therapy areas from Autoimmune, Dermatology and Gastroenterology, and we hope to expand the list of therapy areas year on year.”

Find out more about our Living With reports

Sign up to receive Rapport.

Rapport is our monthly newsletter where we share our latest expertise and experience.